Novartis Sues Noven To Block Generic Dementia Patch

Law360, New York (April 03, 2013, 6:49 PM ET) -- Novartis AG slapped Hisamitsu Pharmaceutical Co. Inc. and subsidiary Noven Pharmaceuticals Inc. with a lawsuit in Delaware on Wednesday, claiming Noven infringed two patents by seeking U.S. regulatory approval for a generic version of Novartis' dementia-treating Exelon patch.

Novartis and patent co-owner LTS Lohmann Therapie-Systeme AG's complaint against Japan-based Hisamitsu and two Noven units asked the court for injunctive relief as well as an order declaring that U.S. Food and Drug Administration approval of Noven's proposed rivastigmine transdermal system can't come before the plaintiffs' rights under...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required